ArticlePediatric blood & cancer2024

A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.

Kristy L Pilbeam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.